Capricor Therapeutics, Inc.(纳斯达克:CAPR)的股票上涨了31%，但其业务仍然 ...
Capricor Therapeutics, Inc. (NASDAQ:CAPR) shareholders have had their patience rewarded with a 31% share price jump in the ...
Why Capricor Therapeutics Stock Is Soaring Tuesday
Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...
Maxim上调Capricor股票目标价并维持买入评级，因FDA最新进展
Maxim Group调整了对Capricor Therapeutics (NASDAQ: CAPR)的展望,将该公司股票的目标价从之前的12.00美元大幅上调至25.00美元。该公司维持对该股的买入评级。 此次调整是在Capricor宣布计划为其细胞疗法产品deramiocel提交生物制品许可申请(BLA)之后做出的。该产品旨在治疗与杜氏肌营养不良症(DMD)相关的心肌病。 在宣布与美国食品和药 ...
Capricor: DMD Treatment Focus With Deramiocel Is Likely To Pay Off
Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...
Capricor surges on plans to seek FDA approval for lead asset
Capricor Therapeutics (CAPR) stock gains as company plans to seek FDA approval for its lead candidate deramiocel (CAP-1002) ...
Capricor Therapeutics计划于10月提交DMD治疗的BLA申请
SAN DIEGO - 专注于细胞和外泌体疗法治疗罕见疾病的生物技术公司Capricor Therapeutics (NASDAQ: CAPR)宣布计划向美国食品和药物管理局(FDA)提交其主要产品候选药物deramiocel的生物制品许可申请(BLA)，用于治疗杜氏肌营养不良症(DMD)患者的心肌病。该公司预计将于2024年10月开始滚动提交流程，并在年底前完成。 这一决定是在最近与FDA讨论后 ...
bovnews15 小时
Capricor Therapeutics Inc (CAPR) Stock Trading Recap
In recent trading, Capricor Therapeutics Inc (CAPR) stock price has shown some volatility, fluctuating 101.95% over the last five trades and 111.45% over the past 30 trades. This represents a notable ...
DMD细胞疗法即将递交上市申请；RNA疗法新锐开辟抗癌新模式
Deramiocel是一种来源于健康人类心脏的基质细胞。它们通过释放包含微RNA、非编码RNA和蛋白的外泌体，改善DMD患者肌肉瘢痕或纤维化以及心脏功能。Deramiocel还显示出有效的免疫调节活性，可能促进细胞再生。目前美国FDA已授予deram ...
Maxim Group维持Capricor Therapeutics(CAPR.US)买入评级，上调目标价至25美元
Maxim Group分析师Jason McCarthy维持$Capricor Therapeutics (CAPR.US)$买入评级，并将目标价从12美元上调至25美元。 根据TipRanks数据显示，该分析师近一年总胜率为24.4%，总平均回报率为-21.9%。 提示: TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考 ...
Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?
Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Capricor Therapeutics Shares Rise in Premarket on Plans to File Application for Deramiocel
Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...
证券之星2 天
HC Wainwright & Co.：重申Capricor Therapeutics(CAPR.US)评级
HC Wainwright & Co.：重申Capricor Therapeutics(CAPR.US)评级，由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。 Capricor Therapeutics（CAPR.US）公司简介：Capricor Therapeutics Inc是一家总部设在美国的生物技术公司，专注于发现、开发和商业化用于治疗疾病的一流生物疗法 ...